Question 16

Voydeya is subject to a REMS program.

Voydeya is a medication that is indeed subject to a Risk Evaluation and Mitigation Strategy (REMS) program, which is designed to ensure that the benefits of the drug outweigh its risks.

A) Vyvanse

Vyvanse is not subject to a REMS program. While it is a controlled substance used for treating ADHD, it does not have the additional safety measures that a REMS entails. This medication is monitored through standard prescribing practices rather than through a specialized risk management strategy.

B) Voydeya

Voydeya is specifically designed to be used under a REMS program due to the potential risks associated with its use. This program includes requirements for healthcare providers and patients to ensure safe administration and monitoring, emphasizing the drug's risks compared to its benefits.

C) Trulicity

Trulicity is not subject to a REMS program. It is an injectable medication used for the management of type 2 diabetes and is regulated by standard safety guidelines rather than a REMS. Thus, it lacks the stringent oversight associated with medications that require such a program.

D) Tivicay

Tivicay, while it is an important antiretroviral medication used for the treatment of HIV, is not subject to a REMS program. It is monitored through regular prescribing practices and does not have the specific risk management requirements that a REMS entails.

Conclusion

Voydeya is the only medication listed that requires a REMS program, reflecting its unique safety considerations. The other options—Vyvanse, Trulicity, and Tivicay—do not involve a REMS, indicating that they are managed through standard safety protocols. This distinction highlights the importance of risk management strategies in certain medications to ensure patient safety.